2-(3-oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: Development and prodrug concept

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9817-9830

  Wilhelm, Adriana ^a   Lopez Garcia, Laura A ^b   Busschots, Katrien ^b   Fröhner, Wolfgang ^a   Maurer, Frauke ^a   Boettcher, Stefan ^a   Zhang, Hua ^b   Schulze, Jörg O ^b   Biondi, Ricardo M ^b   Engel, Matthias ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 (4 IODOPHENYL) 1 (NAPHTHALEN 2 YL) 3 OXOPROPYL)MALONIC ACID; 2 (3 OXO 1 PHENYL 3 (4 (TRIFLUOROMETHYL)PHENYL)PROPYL)MALONIC ACID; 2 (3 OXO 1,3 DIPHENYLPROPYL)MALONIC ACID DERIVATIVE; 5 OXO 3 PHENYL 5 (4 (TRIFLUOROMETHYL)PHENYL)PENTANOIC ACID; BIS(ACETOXYMETHYL) 2 (3 OXO 1 PHENYL 3 (4 (TRIFLUOROMETHYL) PHENYL)PROPYL)MALONIC ACID; DIETHYL 2 (1 (4 CHLOROPHENYL) 3 (4 IODOPHENYL) 3 OXOPROPYL) MALONIC ACID; DIETHYL 2 (3 OXO 1 PHENYL 3 (4 (TRIFLUOROMETHYL)PHENYL)PROPYL) MALONIC ACID; DIMETHYL 2 (3 (4 IODOPHENYL) 1 (NAPHTHALEN 2 YL) 3 OXOPROPYL) MALONIC ACID; MALONIC ACID DERIVATIVE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PRODRUG; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CRYSTAL STRUCTURE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY;

ALLOSTERIC SITE; BINDING SITES; DNA HELICASES; DRUG DESIGN; ENZYME ACTIVATION; HUMANS; IMMUNOBLOTTING; MALONATES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUSCLE CELLS; PRODRUGS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84870011168     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3010477     Document Type: Article

References (60)

1. Pearce, L. R.; Komander, D.; Alessi, D. R. The nuts and bolts of AGC protein kinases Nat. Rev. Mol. Cell Biol. 2010, 11, 9-22
2. Mora, A.; Komander, D.; van Aalten, D. M.; Alessi, D. R. PDK1, the master regulator of AGC kinase signal transduction Semin. Cell Dev. Biol. 2004, 15, 161-170
3. Bayascas, J. R.; Leslie, N. R.; Parsons, R.; Fleming, S.; Alessi, D. R. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(±) mice Curr. Biol. 2005, 15, 1839-1846
4. Garcia-Echeverria, C.; Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer Oncogene 2008, 27, 5511-5526
5. Sato, S.; Fujita, N.; Tsuruo, T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine) Oncogene 2002, 21, 1727-1738
6. Zhu, J.; Huang, J. W.; Tseng, P. H.; Yang, Y. T.; Fowble, J.; Shiau, C. W.; Shaw, Y. J.; Kulp, S. K.; Chen, C. S. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors Cancer Res. 2004, 64, 4309-4318
7. Feldman, R. I.; Wu, J. M.; Polokoff, M. A.; Kochanny, M. J.; Dinter, H.; Zhu, D.; Biroc, S. L.; Alicke, B.; Bryant, J.; Yuan, S.; Buckman, B. O.; Lentz, D.; Ferrer, M.; Whitlow, M.; Adler, M.; Finster, S.; Chang, Z.; Arnaiz, D. O. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 J. Biol. Chem. 2005, 280, 19867-19874
8. Gopalsamy, A.; Shi, M.; Boschelli, D. H.; Williamson, R.; Olland, A.; Hu, Y.; Krishnamurthy, G.; Han, X.; Arndt, K.; Guo, B. Discovery of dibenzo[ c, f ][2,7]naphthyridines as potent and selective 3-phosphoinositide-dependent kinase-1 inhibitors J. Med. Chem. 2007, 50, 5547-5549
9. Islam, I.; Brown, G.; Bryant, J.; Hrvatin, P.; Kochanny, M. J.; Phillips, G. B.; Yuan, S.; Adler, M.; Whitlow, M.; Lentz, D.; Polokoff, M. A.; Wu, J.; Shen, J.; Walters, J.; Ho, E.; Subramanyam, B.; Zhu, D.; Feldman, R. I.; Arnaiz, D. O. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517 Bioorg. Med. Chem. Lett. 2007, 17, 3819-3825
10. Peifer, C.; Alessi, D. R. Small-molecule inhibitors of PDK1 ChemMedChem 2008, 3, 1810-1838
11. Nagashima, K.; Shumway, S. D.; Sathyanarayanan, S.; Chen, A. H.; Dolinski, B.; Xu, Y.; Keilhack, H.; Nguyen, T.; Wiznerowicz, M.; Li, L.; Lutterbach, B. A.; Chi, A.; Paweletz, C.; Allison, T.; Yan, Y.; Munshi, S. K.; Klippel, A.; Kraus, M.; Bobkova, E. V.; Deshmukh, S.; Xu, Z.; Mueller, U.; Szewczak, A. A.; Pan, B. S.; Richon, V.; Pollock, R.; Blume-Jensen, P.; Northrup, A.; Andersen, J. N. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor J. Biol. Chem. 2011, 286, 6433-6448
12. Copps, K. D.; White, M. F. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2 Diabetologia 2012, 55, 2565-2582
13. Bayascas, J. R.; Sakamoto, K.; Armit, L.; Arthur, J. S.; Alessi, D. R. Evaluation of approaches to generation of tissue-specific knock-in mice J. Biol. Chem. 2006, 281, 28772-28781
14. Um, S. H.; Frigerio, F.; Watanabe, M.; Picard, F.; Joaquin, M.; Sticker, M.; Fumagalli, S.; Allegrini, P. R.; Kozma, S. C.; Auwerx, J.; Thomas, G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity Nature 2004, 431, 200-205
15. Um, S. H.; D'Alessio, D.; Thomas, G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1 Cell Metab. 2006, 3, 393-402
16. Sale, E. M.; Sale, G. J. Protein kinase B: signalling roles and therapeutic targeting Cell. Mol. Life Sci. 2008, 65, 113-127
17. Ellwood-Yen, K.; Keilhack, H.; Kunii, K.; Dolinski, B.; Connor, Y.; Hu, K.; Nagashima, K.; O'Hare, E.; Erkul, Y.; Di Bacco, A.; Gargano, D.; Shomer, N. H.; Angagaw, M.; Leccese, E.; Andrade, P.; Hurd, M.; Shin, M. K.; Vogt, T. F.; Northrup, A.; Bobkova, E. V.; Kasibhatla, S.; Bronson, R. T.; Scott, M. L.; Draetta, G.; Richon, V.; Kohl, N.; Blume-Jensen, P.; Andersen, J. N.; Kraus, M. PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models Cancer Res. 2011, 71, 3052-3065
18. Westmoreland, J. J.; Wang, Q.; Bouzaffour, M.; Baker, S. J.; Sosa-Pineda, B. Pdk1 activity controls proliferation, survival, and growth of developing pancreatic cells Dev. Biol. 2009, 334, 285-298
19. Biondi, R. M.; Cheung, P. C.; Casamayor, A.; Deak, M.; Currie, R. A.; Alessi, D. R. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA EMBO J. 2000, 19, 979-988
20. Biondi, R. M.; Kieloch, A.; Currie, R. A.; Deak, M.; Alessi, D. R. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB EMBO J. 2001, 20, 4380-4390
21. Bogan, A. A.; Thorn, K. S. Anatomy of hot spots in protein interfaces J. Mol. Biol. 1998, 280, 1-9
22. Stephens, L.; Anderson, K.; Stokoe, D.; Erdjument-Bromage, H.; Painter, G. F.; Holmes, A. B.; Gaffney, P. R.; Reese, C. B.; McCormick, F.; Tempst, P.; Coadwell, J.; Hawkins, P. T. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B Science 1998, 279, 710-714
23. Anderson, K. E.; Coadwell, J.; Stephens, L. R.; Hawkins, P. T. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B Curr. Biol. 1998, 8, 684-691
24. Beeson, M.; Sajan, M. P.; Dizon, M.; Grebenev, D.; Gomez-Daspet, J.; Miura, A.; Kanoh, Y.; Powe, J.; Bandyopadhyay, G.; Standaert, M. L.; Farese, R. V. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4, 5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise Diabetes 2003, 52, 1926-1934
25. Farese, R. V.; Sajan, M. P.; Standaert, M. L. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes Exp. Biol. Med. (Maywood) 2005, 230, 593-605
26. Frojdo, S.; Vidal, H.; Pirola, L. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans Biochim. Biophys. Acta 2009, 1792, 83-92
27. Chou, M. M.; Hou, W.; Johnson, J.; Graham, L. K.; Lee, M. H.; Chen, C. S.; Newton, A. C.; Schaffhausen, B. S.; Toker, A. Regulation of protein kinase C ζ by PI 3-kinase and PDK-1 Curr. Biol. 1998, 8, 1069-1077
28. Balendran, A.; Biondi, R. M.; Cheung, P. C.; Casamayor, A.; Deak, M.; Alessi, D. R. A 3-phosphoinositide-dependent protein kinase-1 (PDK1) docking site is required for the phosphorylation of protein kinase Cζ (PKCζ) and PKC-related kinase 2 by PDK1 J. Biol. Chem. 2000, 275, 20806-20813
29. Newton, A. C. Protein kinase C: poised to signal Am. J. Physiol.: Endocrinol. Metab. 2010, 298, E395-402
30. Engel, M.; Hindie, V.; Lopez-Garcia, L. A.; Stroba, A.; Schaeffer, F.; Adrian, I.; Imig, J.; Idrissova, L.; Nastainczyk, W.; Zeuzem, S.; Alzari, P. M.; Hartmann, R. W.; Piiper, A.; Biondi, R. M. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds EMBO J. 2006, 25, 5469-5480
31. Stroba, A.; Schaeffer, F.; Hindie, V.; Lopez-Garcia, L. A.; Adrian, I.; Fröhner, W.; Hartmann, R. W.; Biondi, R. M.; Engel, M. 3,5-Diphenylpent-2- enoic acids as allosteric activators of the protein kinase PDK1: Structure-activity relationships and thermodynamic characterisation of binding as paradigms for PIF-binding pocket-targeting compounds J. Med. Chem. 2009, 52, 4683-4693
32. Hindie, V.; Stroba, A.; Zhang, H.; Lopez-Garcia, L. A.; Idrissova, L.; Zeuzem, S.; Hirschberg, D.; Schaeffer, F.; Jorgensen, T. J.; Engel, M.; Alzari, P. M.; Biondi, R. M. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1 Nat. Chem. Biol. 2009, 5, 758-764
33. 15N TROSY experiments Chem. Biol. Drug Des. 2009, 73, 179-188
34. Wei, L.; Gao, X.; Warne, R.; Hao, X.; Bussiere, D.; Gu, X. J.; Uno, T.; Liu, Y. Design and synthesis of benzoazepin-2-one analogues as allosteric binders targeting the PIF pocket of PDK1 Bioorg. Med. Chem. Lett. 2010, 20, 3897-3902
35. Bobkova, E. V.; Weber, M. J.; Xu, Z.; Zhang, Y. L.; Jung, J.; Blume-Jensen, P.; Northrup, A.; Kunapuli, P.; Andersen, J. N.; Kariv, I. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening J. Biol. Chem. 2010, 285, 18838-18846
36. Sadowsky, J. D.; Burlingame, M. A.; Wolan, D. W.; McClendon, C. L.; Jacobson, M. P.; Wells, J. A. Turning a protein kinase on or off from a single allosteric site via disulfide trapping Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 6056-6061
37. Dettori, R.; Sonzogni, S.; Meyer, L.; Lopez-Garcia, L. A.; Morrice, N. A.; Zeuzem, S.; Engel, M.; Piiper, A.; Neimanis, S.; Frodin, M.; Biondi, R. M. Regulation of the interaction between protein kinase C-related protein kinase 2 (PRK2) and its upstream kinase, 3-phosphoinositide-dependent protein kinase 1 (PDK1) J. Biol. Chem. 2009, 284, 30318-30327
38. Xu, C.; Bartley, J. K.; Enache, D. I.; Knight, D. W.; Hutchings, G. J. High Surface Area MgO as a Highly Effective Heterogeneous Base Catalyst for Michael Addition and Knoevenagel Condensation Reactions Synthesis 2005, 19, 3468-3476
39. 3-catalyzed 1,4-addition of 1,2-allenic ketones with diethyl malonate: controlled selective synthesis of beta,gamma-unsaturated enones and α-pyrones J. Org. Chem. 2003, 68, 8996-9002
40. 3-catalyzed Michael addition-lactonization reaction of 1,2-allenyl ketones with electron-withdrawing group substituted acetates. An efficient synthesis of α-pyrone derivatives Org. Lett. 2002, 4, 505-507
41. March, J. The decarboxylation of organic acids J. Chem. Educ. 1963, 40, 212-213
42. 2+ release channels J. Am. Chem. Soc. 2007, 129, 5316-5317
43. Mai, A.; Cheng, D.; Bedford, M. T.; Valente, S.; Nebbioso, A.; Perrone, A.; Brosch, G.; Sbardella, G.; De Bellis, F.; Miceli, M.; Altucci, L. Epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors J. Med. Chem. 2008, 51, 2279-2290
44. Busschots, K.; Lopez-Garcia, L. A.; Lammi, C.; Stroba, A.; Zeuzem, S.; Piiper, A.; Alzari, P. M.; Neimanis, S.; Arencibia, J. M.; Engel, M.; Schulze, J. O.; Biondi, R. M. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. Chem. Biol. 2012, not supplied.
45. Lu, Y.; Shi, T.; Wang, Y.; Yang, H.; Yan, X.; Luo, X.; Jiang, H.; Zhu, W. Halogen bonding - a novel interaction for rational drug design? J. Med. Chem. 2009, 52, 2854-2862
46. Fröhner, W.; Lopez-Garcia, L. A.; Neimanis, S.; Weber, N.; Navratil, J.; Maurer, F.; Stroba, A.; Zhang, H.; Biondi, R. M.; Engel, M. 4-Benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCζ J. Med. Chem. 2011, 54, 6714-6723
47. Lopez-Garcia, L. A.; Schulze, J. O.; Fröhner, W.; Zhang, H.; Süß, E.; Weber, N.; Navratil, J.; Amon, S.; Hindie, V.; Zeuzem, S.; Jørgensen, T. J. D.; Alzari, P. M.; Neimanis, S.; Engel, M.; Biondi, R. M. Allosteric regulation of protein kinase PKCζ by the N-terminal C1 domain and small compounds to the PIF-pocket Chem. Biol. 2011, 18, 1463-1473
48. Olsen, J. A.; Banner, D. W.; Seiler, P.; Obst Sander, U.; D'Arcy, A.; Stihle, M.; Muller, K.; Diederich, F. A fluorine scan of thrombin inhibitors to map the fluorophilicity/fluorophobicity of an enzyme active site: evidence for C-F⋯C = O interactions Angew. Chem., Int. Ed. 2003, 42, 2507-2511
49. Niimi, T.; Orita, M.; Okazawa-Igarashi, M.; Sakashita, H.; Kikuchi, K.; Ball, E.; Ichikawa, A.; Yamagiwa, Y.; Sakamoto, S.; Tanaka, A.; Tsukamoto, S.; Fujita, S.; Tatsuta, K.; Maeda, Y.; Chikauchi, K. Design and synthesis of non-peptidic inhibitors for the Syk C-terminal SH2 domain based on structure-based in-silico screening J. Med. Chem. 2001, 44, 4737-4740
50. Gao, Y.; Luo, J.; Yao, Z. J.; Guo, R.; Zou, H.; Kelley, J.; Voigt, J. H.; Yang, D.; Burke, T. R., Jr. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic J. Med. Chem. 2000, 43, 911-920
51. Fedorov, O.; Marsden, B.; Pogacic, V.; Rellos, P.; Muller, S.; Bullock, A. N.; Schwaller, J.; Sundstrom, M.; Knapp, S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 20523-20528
52. Kroe, R. R.; Regan, J.; Proto, A.; Peet, G. W.; Roy, T.; Landro, L. D.; Fuschetto, N. G.; Pargellis, C. A.; Ingraham, R. H. Thermal denaturation: a method to rank slow binding, high-affinity P38α MAP kinase inhibitors J. Med. Chem. 2003, 46, 4669-4675
53. Jansen, A. B.; Russell, T. J. Some novel penicillin derivatives J. Chem. Soc. 1965, 65, 2127-2132
54. Daehne, W.; Frederiksen, E.; Gundersen, E.; Lund, F.; Morch, P.; Petersen, H. J.; Roholt, K.; Tybring, L.; Godtfredsen, W. O. Acyloxymethyl esters of ampicillin J. Med. Chem. 1970, 13, 607-612
55. Ferres, H. Prodrugs of beta-lactam antibiotics Drugs Today 1983, 19, 499-538
56. Bundgaard, H.; Nielsen, N. M. Esters of N, N -disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents J. Med. Chem. 1987, 30, 451-454
57. D'Arezzo, S.; Incerpi, S.; Davis, F. B.; Acconcia, F.; Marino, M.; Farias, R. N.; Davis, P. J. Rapid nongenomic effects of 3,5,3′-triiodo- l -thyronine on the intracellular pH of L-6 myoblasts are mediated by intracellular calcium mobilization and kinase pathways Endocrinology 2004, 145, 5694-5703
58. James, A. M.; Wei, Y. H.; Pang, C. Y.; Murphy, M. P. Altered mitochondrial function in fibroblasts containing MELAS or MERRF mitochondrial DNA mutations Biochem. J. 1996, 318 (Pt 2) 401-407
59. Zamecnik, P.; Aghajanian, J.; Zamecnik, M.; Goodchild, J.; Witman, G. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3156-3160
60. Niesen, F. H.; Berglund, H.; Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability Nat. Protoc. 2007, 2, 2212-2221